In this issue:
ASC4FIRST: asciminib in newly diagnosed CML
Lenalidomide & obinutuzumab in relapsed indolent non-Hodgkin lymphoma
Tipifarnib for relapsed/refractory PTCL
MRD monitoring to predict long-term remission in follicular lymphoma
Ruxolitinib for relapsed/refractory large granular lymphocytic leukaemia
Treatments for CML during pregnancy
BRUIN: pirtobrutinib + venetoclax ± rituximab in relapsed/refractory CLL
Long-term outcomes of venetoclaxibrutinib in MCL
Acalabrutinib + venetoclax + rituximab in treatment-naïve MCL
Adding bortezomib to induction and/or lenalidomide to maintenance in older patients with MCL
Please login below to download this issue (PDF)